Ozempic Cost: What You’re Actually Paying and Whether It’s Worth It

If you’ve looked up Ozempic recently, you already know the sticker shock is real. The list price for a monthly supply of semaglutide — the active ingredient in both Ozempic and Wegovy — runs roughly $900 to $1,350 per month in the United States without insurance coverage. For a medication you may need to take indefinitely to maintain results, that number deserves serious scrutiny. And according to a 2025 cost-effectiveness analysis published in JAMA Health Forum, it deserves scrutiny at the policy level too: researchers found that semaglutide would need an 81.9% price reduction from its current net price to reach the standard $100,000 per quality-adjusted life-year cost-effectiveness threshold. In other words, the drug works — but at its current price, the math is brutal for most Americans.

That doesn’t mean semaglutide isn’t worth it for certain individuals. It means understanding what you’re buying, what it actually costs over time, and what your alternatives are has never mattered more.

What Ozempic Actually Costs — And Why Insurance Coverage Is Everything

Ozempic was FDA-approved for type 2 diabetes, not weight loss specifically. Wegovy, the higher-dose version of semaglutide, carries the obesity indication. This distinction matters enormously when it comes to insurance coverage. Many commercial insurance plans will cover Ozempic for a diabetic diagnosis with a reasonable copay — sometimes as low as $25 to $50 per month through manufacturer savings programs. The same drug prescribed off-label for weight loss, or Wegovy prescribed for obesity, is a completely different conversation. Many insurance plans, including most Medicaid programs and Medicare until very recently, have excluded coverage for anti-obesity medications entirely.

Without insurance, you’re looking at roughly $900 to $1,000 per month for Ozempic and $1,300 to $1,400 for Wegovy. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) runs in a similar range. Novo Nordisk and Eli Lilly both offer savings cards for commercially insured patients, which can bring costs down significantly — but these programs have income limits and eligibility restrictions. For uninsured or underinsured patients, compounded semaglutide became a popular workaround during the drug shortage period, though the FDA has moved to restrict compounding access as supply stabilizes, making this option increasingly uncertain.

The critical financial reality that doesn’t make it into the marketing is this: these are indefinitely ongoing costs. Real-world data show that 20% to 50% of GLP-1 users discontinue within the first year, with high out-of-pocket costs cited as a primary driver. The weight loss observed in clinical practice also tends to be lower than in trials, largely because patients use lower doses and are less adherent than trial participants — often precisely because of cost pressures limiting dose escalation.

The Long-Term Cost Equation: GLP-1s vs. Surgery vs. Doing Nothing

To understand whether Ozempic is worth the cost, you have to run the full calculation — including what obesity-related disease costs over a lifetime if left unmanaged. The same JAMA Health Forum study modeled outcomes across 126 million eligible U.S. adults and found that tirzepatide would avert over 45,000 obesity cases, 20,000 diabetes cases, and 10,000 cardiovascular disease cases per 100,000 individuals over a lifetime. Semaglutide showed similarly impressive preventive effects. These are real, meaningful health benefits that carry their own avoided costs downstream.

But there’s a competing data point worth taking seriously. A 2025 cohort study in JAMA Surgery using real insurance claims from tens of thousands of patients found that total two-year costs for GLP-1 users averaged $63,483 compared to $51,794 for patients who had bariatric surgery — and the surgery group lost significantly more weight (28.3% vs. 10.3% of body weight). The driving factor was sustained pharmacy costs throughout year two of GLP-1 treatment. Surgery has high upfront costs but no ongoing medication bill. GLP-1s have lower upfront costs but the meter keeps running.

This doesn’t make surgery the automatic answer — it carries its own risks, isn’t appropriate for everyone, and requires a very different lifestyle adjustment. But it reframes how men should think about cost when evaluating their options. A $1,200-per-month medication taken for five years is $72,000. That context changes the conversation.

Remote care programs built around GLP-1 medications offer a partial middle ground. A 12-month retrospective study published in JMIR Formative Research found that a digital-delivery model combining semaglutide or tirzepatide with dietitian coaching produced outcomes closely matching clinical trials — with 95% of tirzepatide users and 83% of semaglutide users achieving at least 10% weight loss at 12 months, while cutting costs 10% to 70% compared to traditional specialist care. Telehealth platforms that prescribe and ship GLP-1 medications directly can reduce overhead, though the drug cost itself remains the largest line item.

For men who want the benefits of these medications but can’t justify the ongoing expense, the practical path involves several moves: checking whether a type 2 diabetes diagnosis qualifies you for Ozempic under your current insurance plan, calling your insurer directly to ask about obesity medication coverage under your specific policy, and applying for manufacturer patient assistance programs if your income qualifies. Comparing GoodRx pricing across local pharmacies can surface meaningful variation — sometimes $100 to $200 per month in difference for the same drug and dose. And if you’re on a GLP-1 and the cost becomes unsustainable, having a proactive conversation with your prescriber about transitioning rather than abruptly stopping is critical, since head-to-head clinical data show meaningful differences between GLP-1 agents in terms of cost, dosing convenience, and magnitude of effect — meaning there may be a more affordable agent that still moves the needle for you.

The Takeaway

Ozempic and its siblings are genuinely impressive medications that produce real, measurable health outcomes. The science is not in question. But at $900 to $1,300 per month with no defined stopping point, cost is an unavoidable part of the decision-making process — one that researchers, policymakers, and patients are all grappling with simultaneously. If you’re considering a GLP-1, go in with eyes open: understand your insurance situation before you fill a prescription, know what the two-year cost projection looks like, and weigh it honestly against alternatives including surgery, structured programs, or aggressive lifestyle intervention. The best treatment is one you can actually sustain — financially and otherwise.